MICURX PHARMACEUTICALS
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
MICURX PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.micurx.com
Total Employee:
11+
Status:
Active
Contact:
510-782-2021
Email Addresses:
[email protected]
Total Funding:
268.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible WordPress Contact Form 7 Baidu Maps
Current Employees Featured
Founder
Investors List
Legend Capital
Legend Capital investment in Series E - MicuRx Pharmaceuticals
DT Capital Partners
DT Capital Partners investment in Series E - MicuRx Pharmaceuticals
Korea Investment Partners
Korea Investment Partners investment in Series E - MicuRx Pharmaceuticals
China Merchants Group
China Merchants Group investment in Series E - MicuRx Pharmaceuticals
Zhongtai Venture Capital
Zhongtai Venture Capital investment in Series E - MicuRx Pharmaceuticals
Yingke Capital
Yingke Capital investment in Series E - MicuRx Pharmaceuticals
Founder Securities
Founder Securities investment in Series E - MicuRx Pharmaceuticals
CARB-X
CARB-X investment in Grant - MicuRx Pharmaceuticals
Sinopharm-CICC
Sinopharm-CICC investment in Series D - MicuRx Pharmaceuticals
Huagai Capital
Huagai Capital investment in Series D - MicuRx Pharmaceuticals
Official Site Inspections
http://www.micurx.com Semrush global rank: 5.37 M Semrush visits lastest month: 650
- Host name: 17.149.96.66.static.eigbox.net
- IP address: 66.96.149.17
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803
More informations about "MicuRx Pharmaceuticals"
MicuRx Pharmaceuticals, Inc.
MicuRx is a global biopharmaceutical company committed to discover, develop, and deliver innovative medicines that address unmet clinical needs. Founded in 2007, MicuRx’s …See details»
Our company - MicuRx Pharmaceuticals, Inc.
MicuRx is a biopharmaceutical company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, we are committed to the discovery, development, and …See details»
MicuRx Pharmaceuticals - Crunchbase Company Profile & Funding
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the …See details»
Our Team - MicuRx Pharmaceuticals, Inc.
Director,Chief Financial Officer,Board Secretary and President of MicuRx USA . Regis A. Vilchez M.D. Ph.D. Chief Medical Officer of MicuRx Pharmaceuticals, Inc. Hong Yuan Ph.D. Deputy General Manager，Chief Clinical Officer . …See details»
MicuRx - Overview, News & Similar companies | ZoomInfo.com
Oct 10, 2023 · View MicuRx (www.micurx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
MicuRx Pharmaceuticals - Products, Competitors, Financials, …
May 8, 2022 · MicuRx Pharmaceuticals is a biotechnology company focused on the development of innovative drugs for infectious diseases. Use the CB Insights Platform to explore MicuRx …See details»
MicuRx Pharmaceuticals, Inc. | Working Group for New TB Drugs
From website www.micurx.com accessed 8/28/2017: "The MicuRx mission is to bring safer and effective antibacterial products for therapy of Gram-positive and Gram-negative infections to …See details»
MicuRx Announces CARB-X US$7.78 Million Funding for ... - PR …
Aug 13, 2020 · MicuRx is a privately held biopharmaceutical company focusing on discovering and developing antibiotics with improved safety profiles to treat resistant bacterial infections.See details»
CARB-X partners with MicuRx to develop a polymyxin antibiotic to …
(BOSTON: March 5, 2018) – CARB-X is teaming up with MicuRx Pharmaceuticals Inc. of Hayward, CA, to support the early development of its polymyxin antibiotic MRX-8 to treat the …See details»
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 …
Oct 18, 2024 · MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of …See details»
Careers - MicuRx Pharmaceuticals, Inc.
We have recruited a strong team of qualified individuals both in the US and in China, which includes seasoned executives that have extensive successful experience in the discovery and …See details»
MicuRx Pharmaceuticals Announces Promising Results from
Oct 7, 2024 · With a mission to address significant unmet medical needs, MicuRx is advancing a portfolio of drug candidates targeting difficult-to-treat infections.See details»
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO …
Feb 9, 2023 · MicuRx is rapidly expanding its business and assembling an international expert team with extensive experience and an innovative spirit to develop a robust global R&D …See details»
MicuRx: Successful Completion of Phase I Clinical Trial for Self ...
SHANGHAI, June 6, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) successfully completed the Phase I clinical trial of its self-developed …See details»
MicuRx Announces CARB-X US$7.78 Million Funding for
Aug 13, 2020 · MRX-8 is a novel polymyxin active against infections caused by multidrug-resistant (MDR) Gram-negative pathogens, including carbapenem-resistant …See details»
Corporate news - MicuRx Pharmaceuticals, Inc.
On July 25, 2023, MicuRx Pharmaceutical Co., Ltd. announced that its independently developed new drug against Gram positive drug-resistant bacteria - MRX-4 for injection sequential oral …See details»
MicuRx gets $7.8M top-up to push new antibiotic into the clinic
Aug 13, 2020 · Now, the Sino-American biotech is topping that up with $7.78 million from a nonprofit focused on antimicrobial resistance to push another asset into human trials. The …See details»
MicuRx Pharmaceuticals Announces Promising Results from MRX …
Oct 8, 2024 · MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of multidrug …See details»
MicuRx Pharmaceuticals Announces Promising Results from MRX …
Oct 8, 2024 · MicuRx Pharmaceuticals is committed to advancing the development of MRX-5 and looks forward to initiating clinical trials in patients to further evaluate its safety and efficacy in …See details»
MicuRx Announces Funding from CARB-X for Innovative Polymyxin ...
Mar 5, 2018 · CARB-X is the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from …See details»